Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharmaceutical MNCs Chalked Up Impressive Growth In China

This article was originally published in PharmAsia News

Executive Summary

Even as the pharmaceutical industry worldwide experiences a slowdown, most MNCs in China chalked up an average growth of over 20 percent in 2007, higher than the previous year's 15 percent. GSK China (including Hong Kong) turned in a 24 percent increase, with prescription drugs jumping to 30 percent, in contrast to its global 2 percent growth. AstraZeneca's sales grew 25 percent in China and Hong Kong while Roche enjoyed a 30 percent hike. Novartis's sales increased by 24.8 percent, with generics revenue surging 27 percent. Little surprise then that pharmaceutical MNCs are stepping up their investment in China and other emerging markets to compensate for their losses in developed countries. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts